Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Regeneron Pharmaceuticals, Inc. < Previous 1 2 3 Next > Regeneron Provides Update on Biologics License Application for Linvoseltamab August 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast August 07, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron Reports Second Quarter 2024 Financial and Operating Results August 01, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation July 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD July 03, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma June 28, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 June 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine June 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN SNY Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma June 16, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) June 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD May 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN SNY Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation May 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN SNY Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO May 23, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine May 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 May 17, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) May 13, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN SNY Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks May 08, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron Announces Investor Conference Presentations May 06, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron Reports First Quarter 2024 Financial and Operating Results May 02, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases April 29, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases April 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO April 24, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) April 22, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma April 07, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 April 01, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Regeneron Provides Update on Biologics License Application for Odronextamab March 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization March 12, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol March 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet March 08, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation February 23, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Tickers REGN < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.